Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 8, 2023, regarding events occurring on March 7, 2023. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Fee: $55,000 (increasing to $60,000 effective April 1, 2023).
- Initial Stock Option Grant: 4,948 shares with an aggregate grant date fair value of $600,000.
- Option Exercise Price: $194.34 per share.
- Future Annual Option Grant Value: Approximately $400,000 (starting in 2024).
Material Changes
The Board of Directors expanded its size from twelve to thirteen members. Peter N. Kellogg was elected to fill the newly created vacancy as a Class II director, with a term expiring at the 2024 annual meeting of stockholders. He is expected to be appointed to the Audit Committee.
Outlook, Risks, and Management Commentary
Management commentary is limited to the details of the new director's compensation package and indemnification agreement. No guidance, outlook, risks, contingencies, or unusual items regarding the company's business operations or financial future are disclosed in this filing.
Key Facts for Investor Verification
- Verify the impact of the Board expansion on corporate governance and committee composition.
- Confirm the vesting schedule for the initial stock option grant (ratably over three years starting one year from the grant date).
- Note the increase in the annual cash fee for non-employee directors effective April 1, 2023.
- Review the exercise price of $194.34 per share relative to the current market price of ALNY common stock.